论文部分内容阅读
目的:总结非清髓性异体外周造血干细胞移植(Allo-PBSCT)治疗实体肿瘤的研究现状,探讨其治疗作用及关键技术。方法:应用Medline、PubMed全文数据库检索系统,以“异基因造血干细胞移植,限制剂量强度,移植物抗肿瘤效应,实体肿瘤”等为关键词,检索1995-2010年的相关文献,以非清髓性异体外周造血干细胞输注此项技术用于晚期实体肿瘤的临床治疗为纳入标准,分析文献30篇。结果:Allo-PBSCT可用于晚期难治性恶性肿瘤患者的治疗,它能够提高患者的生存时间和生活质量,是治疗晚期难治性恶性肿瘤的有效手段之一。但是,此项治疗技术亦存在问题,大多数晚期肿瘤患者体质弱,建立起适合我国晚期癌症患者的限制剂量强度的预处理方案尚需进一步探索;移植相关并发症导致患者死亡是限制此项技术临床应用的瓶颈。结论:Allo-PBSCT治疗晚期难治性恶性肿瘤的临床研究结果令人鼓舞,但是如何降低移植物抗宿主病(GVHD)效应的同时增强移植物抗肿瘤效应(GVT)效应是此项技术能否成功的关键,值得临床进一步深入研究。
Objective: To summarize the research status of allo-PBSCT in the treatment of solid tumors and to explore its therapeutic effect and key technologies. Methods: Using the key words of “allogenic hematopoietic stem cell transplantation, limiting dose intensity, anti-tumor effect of implants, solid tumor” by using Medline and PubMed full-text database retrieval system, the related literatures from 1995 to 2010 were retrieved, Myeloablative allogeneic peripheral blood stem cell infusion of this technology for the treatment of advanced solid tumors for inclusion criteria, analysis of 30 articles. Results: Allo-PBSCT can be used in the treatment of patients with advanced refractory malignancies. It can improve the survival time and quality of life of patients, and is an effective treatment for advanced refractory malignancies. However, this treatment technique is also problematic. Most patients with advanced cancer have weak constitution and need to further explore preconditioning strategies for limiting the dose intensity suitable for advanced cancer patients in our country. The death caused by transplantation-related complications is a limitation of this technique Clinical application of the bottleneck. Conclusions: The results of Allo-PBSCT in the treatment of advanced refractory malignancies are encouraging, but how to reduce the effect of graft versus host disease (GVHD) and enhance the effect of graft anti-tumor effect (GVT) The key to success, it is worth further study in clinical.